id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1102-0005,FDA,FDA-2016-E-1102,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-09-19T04:00:00Z,2017,9,2017-09-19T04:00:00Z,,2017-09-19T13:29:34Z,,0,0,0900006482b4dae8
FDA-2016-E-1102-0004,FDA,FDA-2016-E-1102,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,,2016-12-13T16:11:28Z,,0,0,09000064824012ba
FDA-2016-E-1102-0003,FDA,FDA-2016-E-1102,"Determination of Regulatory Review Period for Purposes of Patent
Extension; GARDASIL 9",Notice,Determinations,2016-12-07T05:00:00Z,2016,12,2016-12-07T05:00:00Z,2017-02-07T04:59:59Z,2016-12-07T14:55:45Z,2016-29303,0,0,09000064823e7105
FDA-2016-E-1102-0001,FDA,FDA-2016-E-1102,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T14:40:39Z,,0,0,0900006481fa1d4a
FDA-2016-E-1102-0002,FDA,FDA-2016-E-1102,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T14:50:12Z,,0,0,09000064822ea236